Ausgabe 2/2024
Inhalt (16 Artikel)
The future of clinical trials—goals, ideas, and discussion
- Open Access
- review
Michael Gnant, Manuela Gili, Magdalena Schwarz, Christian Fesl, Dominik Hlauschek, Anita Jallitsch-Halper, Hannes Fohler
Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence
- Open Access
- short review
Aysegül Ilhan-Mutlu, Elisabeth Sophie Bergen
Treatment-changing news in urogenital cancer—a brief unstructured narrative review based on findings presented at the ESMO 2023 conference
- Open Access
- short review
Alexander Jakob Zgubic, Marianne Leitsmann, Sascha Ahyai, Martin Pichler
Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma
- original report
Changbin Wang, Ran Zhang, Xiaorong Sun, Ligang Xing
Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report
- case report
Nino Rafael Müser, Klaus Kirchbacher, Georg-Christian Funk
Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents
- Open Access
- short review
Gheorghe-Emilian Olteanu, Luka Brcic
Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations
- Open Access
- short review
Yana Sharapova, Sonja Loges, Melanie Janning
Diagnosis and management of mediastinal extragonadal germ cell tumors
- Open Access
- short review
Axel Heidenreich, Pia Paffenholz, David Pfister
Antibody–drug conjugates in ovarian cancer
- Open Access
- short review
Barin Feroz, Christian Marth, Alain Gustave Zeimet
Antibody–drug conjugates in the treatment of lymphoid neoplasms
- Open Access
- short review
Peter Neumeister, Katharina Theresa Prochazka
Brief update on systemic therapies in myeloproliferative neoplasms
- Open Access
- short review
Janine Steichen, Dominik Wolf
Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis
- original report
Giuseppe A. Colloca, Antonella Venturino
